The LUX-Lung3 and LUX-Lung6 clinical trials showed that afatinib improved the clinical symptoms and PFS in patients with NSCLC harboring classical and non-classical EGFR mutations.[10] The LUX-Lung2, LUX-Lung3, and LUX-Lung6 clinical trials in patients with advanced NSCLC harboring non-classical mutations also showed responses to afatinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.